Miro1 protein identified as potential driver of insulin resistance in type 2 diabetes
An accumulation of the protein Miro1 (Mitochondrial Rho GTPase1) in skeletal muscle has been identified as a primary driver of insulin resistance in Type 2 diabetes. Located on the outer membrane of mitochondria, excess Miro1 prevents muscle cells from responding properly to insulin, impairing blood sugar regulation. In preclinical experiments, researchers showed that removing Miro1 reversed this defect and successfully restored insulin responsiveness.
The research, published in Nature Communications, examined the protein across cell models, preclinical trials, and human patients. In a randomized controlled trial involving individuals with obesity and Type 2 diabetes, participants performing aerobic exercise experienced a significant drop in muscle Miro1 levels alongside improved insulin sensitivity and energy production, providing a biological mechanism for exercise's therapeutic benefits.
The study was conducted by Dr. John P. Kirwan, Elizabeth Heintz, and Christopher Axelrod across LSU's Pennington Biomedical Research Center and the University of Oklahoma's Harold Hamm Diabetes Center. The authors note that identifying Miro1 offers a concrete new target for future drugs that could work alongside exercise to improve blood sugar control.
Continue in the app — vote & join in ➔